Krakowski Szpital Specjalistyczny im. Jana Pawła II – szpital w Krakowie mieszczący się przy ul. Prądnickiej 80; od 1990 nosi imię Jana Pawła II.

During the past decade, Krakowski Szpital Specjalistyczny im. Jana Pawla II conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 18 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 10 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" #1 sponsor was "Pfizer" with 7 trials, followed by "Actelion" with 3 trials sponsored, "Edwards Lifesciences" with 3 trials sponsored, "John Paul II Hospital, Krakow" with 3 trials sponsored and "Medtronic Cardiac Rhythm and Heart Failure" with 3 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" #1 collaborator was "National Center for Research and Development, Poland" with 4 trials as a collaborator, "KCRI" with 3 trials as a collaborator, "ABX CRO" with 1 trials as a collaborator, "AG Mednet Inc." with 1 trials as a collaborator and "Advanced Clinical, LLC" with 1 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" are "Pulmonary Arterial Hypertension" (7 trials), "Heart Failure" (5 trials), "Myocardial Infarction" (4 trials), "Chronic Thromboembolic Pulmonary Hypertension" (3 trials) and "Mitral Valve Insufficiency" (3 trials). Many other conditions were trialed in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" in a lesser frequency.

Most popular intervention types in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" are "Drug" (33 trials), "Device" (15 trials), "Biological" (12 trials), "Other" (6 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Carboplatin" (4 trials), "Placebos" (3 trials), "Atezolizumab" (2 trials) and "CardioCell" (2 trials). Other intervention names were less common.

The vast majority of trials in "Krakowski Szpital Specjalistyczny im. Jana Pawla II" are 62 trials for "All" genders.

Currently, there are NaN active trials in "Krakowski Szpital Specjalistyczny im. Jana Pawla II". 1 are not yet recruiting, 15 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Krakowski Szpital Specjalistyczny im. Jana Pawla II, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Krakowski Szpital Specjalistyczny im. Jana Pawla II, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 10 trials that are defined as “Not Applicable".

Krakowski Szpital Specjalistyczny im. Jana Pawla II has several departments that took part in Clinical trials: "Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn" - 7 trials, "Szpital Jana Pawla II Oddzial Neuroinfekcji" - 5 trials, "Krakowski Szpital Specjalistyczny im. Jana Pawła II; Oddz. Klin. Chir. Klatki Piersiowej i Onkol." - 3 trials, "Krakowski Szpital Specjalistyczny im. Jana Pawła II; Oddział Onkologiczny" - 2 trials